Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

Benzinga Newsdesk www.benzinga.com Negative 82.8%

Neg 82.8% Neu 0% Pos 0%

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.